Drug intelligence / Profile preview

Sorafenib MMC

Development stage: Phase 1
Lead developer: Disruptive Pharma
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Administration: Oral

Overview

DPH001 is an improved oral formulation of the protein kinase inhibitor sorafenib, developed by Disruptive Pharma using a proprietary mesoporous magnesium carbonate (MMC) drug delivery platform. Sorafenib is approved for the treatment of hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and certain types of thyroid cancer. The DPH001 formulation leverages MMC to stabilize sorafenib in an amorphous state, enhancing its solubility and bioavailability. Preclinical studies have demonstrated that DPH001 achieves bioequivalent exposure at 50% of the standard active pharmaceutical ingredient (API) dose compared to conventional NEXAVAR, with improved absorption and reduced inter-patient variability. This reformulation aims to provide similar efficacy with potentially fewer side effects due to lower dosing requirements[1][2][5].

Brand names: NEXAVAR
Other names: MMC sorafenibmesoporous magnesium carbonate sorafenibDPH001DPH-001DPH 001

Targets

BRAF (B-Raf proto-oncogene, serine/threonine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)FLT3 (Fms related receptor tyrosine kinase 3)VEGFR4 (Vascular endothelial growth factor Receptor-3)HTR2B (5-Hydroxytryptamine Receptor 2B)VEGFR2 (Vascular endothelial growth factor receptor 2)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)RAF1 (c-Raf-1 (Y340D/Y341D))

Beyond the preview

Go deeper on Sorafenib MMC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sorafenib MMC.